Ironwood Pharmaceuti (IRWD) Stock Price, Quote & News

Company Profile

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA name...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 621 7722

Fax: 617 494 0480

Website: ironwoodpharma.com

Address:

100 Summer Street, Suite 2300, Boston, United States

TeeMan123 May. 13 at 2:59 PM

$IRWD after everything this mgmt team and board has done, why the fk can’t they have the brains to at least comment on the guide with such an announcement.

1 · Reply

Nibbler May. 13 at 2:58 PM

$IRWD

0 · Reply

StockTwitsGhost May. 13 at 2:51 PM

$IRWD The 2026 Proxy Statement contains an explicit Golden Parachute provision in the section titled "Potential Payments Upon Termination or Change in Control." This legal language mandates that if a "Change in Control" (buyout) occurs, the company must provide executive officers, specifically including CFO Martini, a cash payout of 1.5x to 2x their base salary and bonus, along with 100% accelerated vesting of all equity. Crucially, management can carve out exceptions for a departing executive through a "tail" provision, which ensures that even if he leaves shortly before a deal is signed, he still receives the full multi-million dollar payout instead of the "forfeiture" currently shown on paper.

1 · Reply

Solaf May. 13 at 2:51 PM

$IRWD I would say what is dead may never die but this company killed us a dozen of times last 2 years.

0 · Reply

Bio_Invest101 May. 13 at 2:50 PM

$IRWD Small but very high percentage and this company never owned more than 100 K shares since 2013 until now Mackenzie Financial Corp reports 4,751.30% increase in ownership of IRWD / Ironwood Pharmaceuticals, Inc. On May 13, 2026 - Mackenzie Financial Corp filed a 13F-HR form disclosing ownership of 560,034 shares of Ironwood Pharmaceuticals, Inc. (US:IRWD) valued at $1,965,719 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 18, 2026 disclosing 11,544 shares of Ironwood Pharmaceuticals, Inc.. This represents a change in shares of 4,751.30% during the quarter. The current value of the position is $2,290,539 USD.

0 · Reply

Bio_Invest101 May. 13 at 2:41 PM

$IRWD so at least for the past 4 weeks the SI reached record highs with longest DTC over 10 days. They knew The CFO was leaving so they’re not concerned even the 1st Q ER results were very good and full yr guides honored. Top executives leaving is normal and there’re so many ways to handle this event and news better but Tom choses to act irresponsibly knowing the news will hurt the SP but why ? Do they all want a lower VWAP to get the deal done?

0 · Reply

revuelto May. 13 at 2:23 PM

$IRWD had a chat with Greg last year…seemed like a good guy….I can only hope this is just house cleaning..sus sus sus

0 · Reply

Solaf May. 13 at 2:02 PM

$IRWD CFO resigned?

2 · Reply

TeeMan123 May. 13 at 1:55 PM

$IRWD these fking morons.. let the ceo resign but reaffirm guidance, everyone thinks these morons are miss managing the guide again

0 · Reply

Bio_Invest101 May. 13 at 12:29 PM

$IRWD Young CFO left “not due to Financial reports related issues or disagreement” … but maybe with Tom and BoD not executing a sell the company decision?? Btw he left without his free RSU grants next month! Interesting https://d18rn0p25nwr6d.cloudfront.net/CIK-0001446847/763b0b1b-54db-424f-bb56-c7a1e8aa93e0.pdf

1 · Reply

Ironwood Pharmaceuticals Earnings Call Transcript: Q1 2026

May 7, 2026, 7:05 AM EDT - 6 days ago

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

2026-05-04T11:11:53.000Z - 9 days ago

Ironwood presents new findings at DDW 2026 from survey treatment of SBS

May 4, 2026, 7:05 AM EDT - 9 days ago

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

Apr 30, 2026, 4:05 PM EDT - 12 days ago

Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call

2026-04-23T11:25:41.000Z - 20 days ago

Ironwood to present data from Landmark survey on SBS

Apr 23, 2026, 7:05 AM EDT - 20 days ago

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

SBS

Mar 11, 2026, 4:00 PM EDT - 2 months ago

Ironwood Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026

Mar 4, 2026, 4:05 PM EST - 2 months ago

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

2026-02-26T11:08:56.000Z - 2 months ago

Ironwood price target raised to $10 from $8 at Citizens

Feb 25, 2026, 8:30 AM EST - 2 months ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 25, 2026, 7:05 AM EST - 2 months ago

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook

Feb 18, 2026, 4:21 PM EST - 2 months ago

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call

2026-01-05T12:37:19.000Z - 4 months ago

Craig-Hallum upgrades Ironwood to Buy following 2026 guidance

2026-01-05T12:20:08.000Z - 4 months ago

Ironwood upgraded to Buy from Hold at Craig-Hallum

2026-01-05T10:15:33.000Z - 4 months ago

Ironwood upgraded to Outperform from Market Perform at Citizens

2026-01-04T23:25:05.000Z - 4 months ago

Ironwood price target raised to $5 from $3 at Wells Fargo

2026-01-02T17:29:08.000Z - 4 months ago

Why Did Ironwood Pharma Stock (IRWD) Jump 30% Today?

PFE

Jan 2, 2026, 7:05 AM EST - 4 months ago

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

2025-11-26T15:10:47.000Z - 6 months ago

Ironwood price target raised to $3.80 from $1.70 at Craig-Hallum

Nov 10, 2025, 7:05 AM EST - 6 months ago

Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance

Oct 24, 2025, 8:10 AM EDT - 7 months ago

Ironwood Stair & Rail Inc. Recognised With 2025 Consumer Choice Award for Stairs and Railings in Southern Alberta

Aug 7, 2025, 7:05 AM EDT - 9 months ago

Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance

May 7, 2025, 12:00 PM EDT - 1 year ago

Ironwood Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 7:05 AM EDT - 1 year ago

Ironwood Pharmaceuticals Reports First Quarter 2025 Results

Apr 25, 2025, 7:05 AM EDT - 1 year ago

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

Apr 22, 2025, 4:05 PM EDT - 1 year ago

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support

Apr 14, 2025, 7:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Industry Veteran Launches Ironwood III With Substantial Equity Commitment From Kayne Anderson Energy Infrastructure Fund

Feb 27, 2025, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance

Feb 20, 2025, 4:00 PM EST - 1 year ago

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call

Jan 29, 2025, 4:30 PM EST - 1 year ago

Ironwood Pharmaceuticals Transcript: Status Update

Jan 29, 2025, 4:05 PM EST - 1 year ago

Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future

Jan 17, 2025, 8:07 AM EST - 1 year ago

Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications

Dec 4, 2024, 12:30 PM EST - 1 year ago

Ironwood Pharmaceuticals Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 4:01 PM EST - 1 year ago

Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 2:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2024

Nov 13, 2024, 4:01 PM EST - 1 year ago

Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024

Oct 24, 2024, 4:00 PM EDT - 1 year ago

Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call

Sep 5, 2024, 2:15 PM EDT - 1 year ago

Ironwood Pharmaceuticals Transcript: 2024 Wells Fargo Healthcare Conference

Aug 29, 2024, 4:01 PM EDT - 1 year ago

Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Reports Second Quarter 2024 Results

Jul 25, 2024, 4:00 PM EDT - 1 year ago

Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call

Jun 18, 2024, 9:00 AM EDT - 2 years ago

Ironwood Pharmaceuticals Transcript: AGM 2024

Jun 6, 2024, 9:00 AM EDT - 2 years ago

Ironwood Pharmaceuticals Transcript: Jefferies 2024 Global Healthcare Conference

May 30, 2024, 4:01 PM EDT - 2 years ago

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

TeeMan123 May. 13 at 2:59 PM

$IRWD after everything this mgmt team and board has done, why the fk can’t they have the brains to at least comment on the guide with such an announcement.

1 · Reply

Nibbler May. 13 at 2:58 PM

$IRWD

0 · Reply

StockTwitsGhost May. 13 at 2:51 PM

1 · Reply

Solaf May. 13 at 2:51 PM

$IRWD I would say what is dead may never die but this company killed us a dozen of times last 2 years.

0 · Reply

Bio_Invest101 May. 13 at 2:50 PM

0 · Reply

Bio_Invest101 May. 13 at 2:41 PM

0 · Reply

revuelto May. 13 at 2:23 PM

$IRWD had a chat with Greg last year…seemed like a good guy….I can only hope this is just house cleaning..sus sus sus

0 · Reply

Solaf May. 13 at 2:02 PM

$IRWD CFO resigned?

2 · Reply

TeeMan123 May. 13 at 1:55 PM

$IRWD these fking morons.. let the ceo resign but reaffirm guidance, everyone thinks these morons are miss managing the guide again

0 · Reply

Bio_Invest101 May. 13 at 12:29 PM

1 · Reply

discussionbo7 May. 12 at 9:58 PM

$MRNA $SLS $TEM $IRWD health sector is coming

0 · Reply

MalekJ May. 11 at 11:34 PM

$IRWD Everyone serves their own agenda.

0 · Reply

StockTwitsGhost May. 11 at 10:52 PM

$IRWD You sounds more like a person playing a character of the "humble observer", while clearly possessing the vocabulary and mechanical understanding of a professional fund manager or a high-net-worth institutional trader.

1 · Reply

StockTwitsGhost May. 11 at 10:52 PM

$IRWD Your response is notable for what it completely avoids saying. You offered no denial, no correction, and no engagement with the observation whatsoever, pivoting instead to IRWD commentary that undermines itself. You describe yourself as a Johnny come lately unaware of the full extent of IRWD’s LINZESS patent position, yet your own prior posts on this platform demonstrate precise delta hedging analysis against specific strikes ahead of Opex, which is not the language of someone casually stumbling into a trade. The EBITDA framing only adds to the inconsistency, with IRWD’s EBITDA sitting around $120 million against a market cap north of $600 million, making the 2x characterization off by a meaningful margin. A claim of ignorance about LINZESS patents that contradicts the sophistication visible elsewhere in your posting history. You had every opportunity to simply say you are not who people might think you are. You chose not to.

0 · Reply

Bio_Invest101 May. 11 at 9:46 PM

$IRWD Interesting Total SI stays the same but DTC cut half from 10 to 5

1 · Reply

StockTwitsGhost May. 11 at 7:45 PM

$IRWD Interesting thematic overlaps across posts by @lucullus1 on Stocktwits, Lucullus Surveyor 1 on Cloudy Nights & adenner1 on X. Sarissa Capital’s Macedonian pike namesake, to Lucullus the Roman General tied to Hellenistic-Macedonian conflict known for immense wealth, patronage of arts/sciences & his strategic victories in the East. Lucullus Surveyor 1 has discussed advanced optics like ion milled surfaces & Lyot coronagraphs, adenner1 references Zeiss systems & HP spectrum analyzers & lucullus1 mentions a 12 inch Newtonian (an advanced telescope) here on Stocktwits. lucullus1 watchlists emphasize biotech names like BIIB, ABBV & M&A situations such as CELG, MYOV, SPLK. All accounts joined in 2012 & 2013 & incorporate the number 1 in some form. While the patterning is interesting, it is not sufficient to support any meaningful conclusion. 🔭🔬 🧬🔍 https://stocktwits.com/lucullus1/message/607057113

1 · Reply

Bio_Invest101 May. 11 at 6:58 PM

$IRWD On May 11, 2026 - Federated Hermes, Inc. filed a 13F-HR form disclosing ownership of 3,348,806 shares of Ironwood Pharmaceuticals, Inc. (US:IRWD) valued at $11,754,309 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 3,318,137 shares of Ironwood Pharmaceuticals, Inc.. This represents a change in shares of 0.92% during the quarter. On May 11, 2026 - Connor, Clark & Lunn Investment Management Ltd. filed a 13F-HR form disclosing ownership of 1,835,424 shares of Ironwood Pharmaceuticals, Inc. (US:IRWD) valued at $6,442,338 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 1,990,927 shares of Ironwood Pharmaceuticals, Inc.. This represents a change in shares of -7.81% during the quarter

0 · Reply

mkmike396 May. 11 at 2:18 PM

$IRWD I’m feeling very bullish after that earnings

0 · Reply

StockTwitsGhost May. 10 at 11:12 AM

$IRWD The mechanical explanation and the intentional explanation are two different claims and you can’t lean on both at once. Passive delta unwind means you wait it out. Active defense means someone has a stop that gets run when this clears five. Those have opposite implications and the distinction matters. What makes the setup interesting is that gamma mechanics above five aren’t a mirror of what’s happening below it. Delta decay below the strike is gradual, but gamma is highest right at the money, so the moment this pushes through, MMs aren’t just buying, they’re buying faster the higher it goes. Eighteen million short shares don’t get to pick their timing when that’s happening underneath them. Dimensional added 529% last quarter, Millennium added 186%. Those shops run systematic models with hard drawdown limits and they don’t accumulate into high short interest names on vibes. They flagged this cheap on the numbers and sized up.

1 · Reply

OsmanAtasoy May. 9 at 11:18 AM

$IRWD Wells Fargo $5.00 "Hold" on Tuesday. Earnings beat on Thursday. No strategic alternatives questions asked at the earnings call. Total silence from analysts on Friday. Is this business as usual for this stock, or is there something interesting going on in the background?

2 · Reply

lucullus1 May. 9 at 5:04 AM

$IRWD the narrative that this is manipulated by Market Malers is likely False. Market Makers will be delta hedged against the $4,5 ,6 calls due in May. By that I mean they will be long the stock to cover their exposure. As that delta fades into Opex they will be forced sellers. It’s mechanical not manipulation. Now there maybe others manipulating because they want to acquire the stock at a low price and the release of the analyst report 2 days before results does seem suspicious 🤷‍♂️. I must say I sold my $4 calls on the day before the number because of all the blocky volume which appeared above $4.7 ish. Somebody plainly was keeping down Great results but remember the future income of this company is uncertain at this point. Linzess revenue to drop dramatically from 2029 onwards. It maybe replaced by other drugs but that is uncertain. What we do know is somebody with deep pockets would like the price lower and they are likely to succeed in their endeavour.

1 · Reply

Bio_Invest101 May. 8 at 9:37 PM

$IRWD So Vanguard shows their ownership now after the internal changes On May 8, 2026 - Vanguard Capital Management Llc filed a 13F-HR form disclosing ownership of 6,097,454 shares of Ironwood Pharmaceuticals, Inc. (US:IRWD) valued at $21,402,064 USD as of March 31, 2026 On May 8, 2026 - Vanguard Portfolio Management Llc filed a 13F-HR form disclosing ownership of 6,682,037 shares of Ironwood Pharmaceuticals, Inc. (US:IRWD) valued at $23,453,950 USD as of March 31, 2026. On May 8, 2026 - Vanguard Fiduciary Trust Co filed a 13F-HR form disclosing ownership of 988,630 shares of Ironwood Pharmaceuticals, Inc. (US:IRWD) valued at $3,470,091 USD as of March 31, 2026. On May 8, 2026 - Vanguard Global Advisers, LLC filed a 13F-HR form disclosing ownership of 591,489 shares of Ironwood Pharmaceuticals, Inc. (US:IRWD) valued at $2,076,126 USD as of March 31, 2026.

1 · Reply

Market Cap	679.95M
Revenue (ttm)	296.15M
Net Income (ttm)	24.02M
EPS (ttm)	N/A
PE Ratio	6.92
Forward PE	4.80
Profit Margin	8.11%
Debt to Equity Ratio	-2.69

Volume	1,862,600
Avg Vol	2,492,668
Day's Range	N/A - N/A
Shares Out	163.06M
Stochastic %K	17%
Beta	0.29
Analysts	Sell
Price Target	$6.10